Alembic Pharmaceuticals has reported strong financial performance during the year ended March 2012 and declared equity dividend of 70 per cent (Rs.1.40 per share). The company's net profit for the year went up by 52.4 per cent to Rs.130.14 crore from Rs.85.39 crore in the previous year. Its net sales moved up by 22 per cent to Rs.1,462 crore from Rs.1,199 crore. With better growth in profits, its earnings per share touched to Rs.6.90 from Rs.4.53 in the last year.

Alembic's domestic sales increased by 11 per cent and exports by 41 per cent. The domestic formulation sales growth was at 13 per cent with sales of Rs.783 crore as against Rs.693 crore in the previous year. It maintained market share of 1.75 per cent. The cumulative ANDA filings reached to 45 and it received 19 approval. It also filed 62 DMFs so far.

Its API exports improved by 55 per cent to Rs.279 crore as against Rs.180 crore and domestic API business recorded sales of Rs.94 crore as compared to Rs.94.51 crore.

The company has set up a state of art 90 bedded bio equivalence centre capable of carrying out 100 pilot/pivotal studies every year. It is now implementing expansion programme to enhance its capacity from existing 2.6 billion tablets/capsules to 5 billion per annum.